Trading Report: Today: Boston Common Asset Management LLC Sold shares of GlaxoSmithKline PLC (GSK)

Today: Boston Common Asset Management LLC Sold shares of GlaxoSmithKline PLC (GSK)

Boston Common Asset Management LLC lowered its position in GlaxoSmithKline PLC (NYSE:GSK) by 9.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,865 shares of the pharmaceutical company’s stock after selling 1,300 shares during the period. Boston Common Asset Management LLC’s holdings in GlaxoSmithKline PLC were worth $555,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in GSK. FMR LLC raised its stake in GlaxoSmithKline PLC by 29.8% in the second quarter. FMR LLC now owns 20,701,378 shares of the pharmaceutical company’s stock worth $897,198,000 after buying an additional 4,757,238 shares during the period. Thornburg Investment Management Inc. raised its stake in GlaxoSmithKline PLC by 188.7% in the second quarter. Thornburg Investment Management Inc. now owns 1,025,410 shares of the pharmaceutical company’s stock worth $44,441,000 after buying an additional 670,284 shares during the period. Ameriprise Financial Inc. raised its stake in GlaxoSmithKline PLC by 24.7% in the second quarter. Ameriprise Financial Inc. now owns 3,038,134 shares of the pharmaceutical company’s stock worth $132,800,000 after buying an additional 602,693 shares during the period. Chartwell Investment Partners LLC raised its stake in GlaxoSmithKline PLC by 519.1% in the second quarter. Chartwell Investment Partners LLC now owns 561,735 shares of the pharmaceutical company’s stock worth $24,346,000 after buying an additional 471,005 shares during the period. Finally, Nationwide Fund Advisors acquired a new stake in GlaxoSmithKline PLC during the third quarter worth approximately $15,399,000. Institutional investors and hedge funds own 8.67% of the company’s stock.

GlaxoSmithKline PLC (NYSE:GSK) traded down 1.03% during mid-day trading on Monday, hitting $38.46. The company’s stock had a trading volume of 1,723,021 shares. The firm has a market cap of $93.57 billion, a price-to-earnings ratio of 253.03 and a beta of 0.93. GlaxoSmithKline PLC has a 52-week low of $37.65 and a 52-week high of $45.58. The firm has a 50 day moving average of $40.10 and a 200-day moving average of $42.40.

The business also recently declared a dividend, which will be paid on Thursday, January 12th. Stockholders of record on Friday, November 4th will be issued a dividend of $0.459 per share. The ex-dividend date is Wednesday, November 2nd. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 1,533.33%.

GSK has been the topic of a number of research analyst reports. Bank of America Corp. restated a “buy” rating and set a $50.00 price target on shares of GlaxoSmithKline PLC in a research report on Tuesday, September 20th. Citigroup Inc. reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday, August 10th. BNP Paribas lowered GlaxoSmithKline PLC from a “neutral” rating to an “underperform” rating in a research report on Tuesday, September 13th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Friday, September 16th. Finally, Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, August 2nd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $48.20.

In related news, major shareholder Plc Glaxosmithkline purchased 66,500 shares of the stock in a transaction dated Monday, October 24th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $931,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.00% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Related posts

Leave a Comment